Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies

Mallik Angalakuditi, Rita F Seifert, Risa P Hayes, Michael P O'Leary, Lars Viktrup, Mallik Angalakuditi, Rita F Seifert, Risa P Hayes, Michael P O'Leary, Lars Viktrup

Abstract

Background: To assess the measurement properties of the Benign Prostatic Hyperplasia Impact Index (BII) for use in men with Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) treated with tadalafil.

Methods: Data from a dose-titration (Study 1) and a dose-finding placebo-controlled (Study 2) tadalafil studies of men 45 years of age or older with moderate to severe LUTS (N = 281; N = 1053) were included in this post-hoc analysis. Measures included the BII, International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (IPSS-QoL), LUTS Global Assessment Question, uroflowmetry measure peak flow rate (Qmax) and postvoid residual volume (PVR). Spearman rank and Pearson correlation coefficients were computed between the BII score and the other measures at each visit. Wilcoxin two-sample tests, t-tests and general linear modeling compared BII scores of subjects with global ratings of improvement versus no improvement, and subjects taking tadalafil versus placebo. Effect size, standardized response mean and Guyatt's responsiveness statistic were calculated for BII and IPSS change scores.

Results: There were high correlations between BII and IPSS & IPSS-QoL and low correlations between BII and Qmax & PVR at each visit. There were significant differences in BII at the End-of-Study Visit between subjects reporting improvement versus subjects reporting no improvement (Studies 1 and 2, P < .0001) and subjects taking tadalafil versus subjects taking placebo (Study 1, P = .0045; Study 2, P = .0064). The BII and IPSS were both responsive to change.

Conclusions: Results show that the BII is reliable, shows responsiveness to change in patients with BPH-LUTS, and demonstrates construct validity.

References

    1. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(suppl 9):S3–S10.
    1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3–S14.
    1. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008;62(1):18–26. doi: 10.1111/j.1742-1241.2007.01635.x.
    1. American Urologic Association (AUA) Practice Guidelines Committee; AUA Guideline on Management of Benign Prostatic Hyperplasia (2003) Chapter 1: Diagnosis and Treatment Recommendations. J Urol. 2003;170(2 Pt 1):530–537.
    1. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urol. 2001;58(6 Suppl1):25–32. doi: 10.1016/S0090-4295(01)01300-0.
    1. de la Rosette J, Alivizatos G, Madersbacher S, Rioja Sanz C, Nordling J, Emberton M, Gravas S, Michel MC, Oelke M, (European Association of Urology) Guidelines on benign prostatic hyperplasia. 2010. Accessed January 12.
    1. Barry MJ, Fowler FL, O'Leary MP, Bruskewitz RC, Holtgreve HL, Mebust WK. Cockett ATK (The Measurement Committee of the American Urological Association) The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557.
    1. Barry MJ, Fowler FL, O'Leary MP, Bruskewitz RC, Holtgreve HL, Mebust WK, Cockett ATK. Measuring disease-specific health status in men with benign prostatic hyperplasia Measurement Committee of The American Urological Association. Med Care. 1995;33:AS145–AS155. doi: 10.1097/00005650-199508000-00003.
    1. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on both due to symptoms, quality of life and global outcome, and factors predicting response. J Urol. 1998;160:1358–1367. doi: 10.1016/S0022-5347(01)62536-9.
    1. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int. 2003;92:262–266. doi: 10.1046/j.1464-410X.2003.04310.x.
    1. Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int. 2006;98:83–88. doi: 10.1111/j.1464-410X.2006.06241.x.
    1. Marklund-Bau H, Edéll-Gustafsson U, Spångberg A. Bothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction. Scand J Urol Nephrol. 2007;41:32–41. doi: 10.1080/00365590601068926.
    1. Barry MJ, Williford WO, Chang W, Machi M, Jones KM, Walker-Corkery E, Lepor H. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154:1770–1774. doi: 10.1016/S0022-5347(01)66780-6.
    1. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Urol. 2004;5:251–257.
    1. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–1407. doi: 10.1016/j.juro.2006.11.037.
    1. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol. 2008;180:1228–1234. doi: 10.1016/j.juro.2008.06.079.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334. doi: 10.1007/BF02310555.
    1. George D, Mallery P. SPSS for Windows step by step: A simple guide and reference, 11.0 update. 4. Boston, Allyn & Bacon; 2003.
    1. Guilford JP, Fruchter B. Fundamental statistics in psychology and education. 5. New York, McGraw-Hill; 1973.
    1. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes. 2006;4:89. doi: 10.1186/1477-7525-4-89.
    1. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol. 2000;53:459–468. doi: 10.1016/S0895-4356(99)00206-1.
    1. Stage CA, Hairston JC. Symptom Scores: Mumbo Jumbo or Meaningful Measures? Curr Urol Rep. 2005;6:251–256. doi: 10.1007/s11934-005-0017-2.
    1. O'Leary MP, Wei JT, Roehrborn CG, Miner M. BPH Registry and Patient Survey Steering Committee. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int. 2008;101:1531–1535. doi: 10.1111/j.1464-410X.2008.07574.x.
    1. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C. UrEpik Study Group. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int. 2003;92:575–580. doi: 10.1046/j.1464-410X.2003.04448.x.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever